Portfolio

Amber Bio is pioneering new RNA editing modalities to treat previously undruggable patient populations.

INDICATIONS
Undisclosed

MODALITY
Multi-kb RNA-editing platform

STAGE
Discovery/Preclinical

Private
RD Fund 2

Atsena Therapeutics is developing novel AAV-based gene therapies for monogenic inherited retinal diseases.

INDICATIONS
LCA1, XLRS, USH1B, STGD

MODALITY
Novel AAV-based gene therapy

STAGE
Clinical

Private
RD Fund 1

CheckedUp is a physician-founded, physician-run patient education company offering tech-enabled patient engagement solutions.

INDICATIONS
Healthcare Technology Platform

Acquired by Rockbridge
RD Fund 1

Nacuity is developing targeted therapies aimed at preventing oxidative tissue damage, a driver of blinding eye disease.

INDICATIONS
RP, Nephropathic Cystinosis

MODALITY
Oral small molecule anti-oxidant

STAGE
Clinical

Private
RD Fund 1

Nayan was developing mutation agnostic therapies for IRD’s that preserve cone function by downregulation of rod-specific genes.

INDICATIONS
Mutation Independent IRD’s

MODALITY
Small-molecule

Dissolved
RD Fund 1

NVasc is an early-stage ophthalmology company focused on treating the dry AMD spectrum through choroidal and retinal revascularization.

INDICATIONS
Dry AMD/GA

MODALITY
LIFR-agonist for revascularization

STAGE
Discovery/Preclinical

Private
RD Fund 2

Opus is a mission based AAV gene therapy company created for treatment of inherited retinal diseases

INDICATIONS
LCA5, BEST1, RDH12, MERTK

MODALITY
AAV-based gene therapy

STAGE
Clinical

Private
RD Fund 1&2

Perceive Bio aims to target risk alleles for dry AMD and GA, target regulation of the complement system, and key retinal neuroprotective pathways.

INDICATIONS
Dry AMD/GA, Neuroprotection

MODALITY
AAV-based gene therapy

STAGE
Clinical

Private
RD Fund 2

SalioGen is developing a novel mammallian-derived enzyme, saliogase, for editing, replacing or augmenting DNA without double-strand breaks or relying on host repair or homologous recombination.

INDICATIONS
STGD

MODALITY
SalioGase editing platform

STAGE
Discovery

Private
RD Fund 2

SparingVision is a genomic medicine company developing mutation independent and dependent therapies designed to prevent retinal degeneration.

INDICATIONS
Mid and Late stage mutation independent RP

MODALITY
novel AAV gene therapy delivery

STAGE
Clinical

Private
RD Fund 1

Stargazer was developing a visual cycle modulator aimed at reducing pathologic accumulation of cytotoxic retinoids in the retina.

INDICATIONS
STGD, Dry AMD

MODALITY
Small Molecule

Solvent Dissolution
RD Fund 1

Vedere Bio I  leveraged a mutation agnostic optogenetic technology with the aim of restoring vision due to photoreceptor cell death. 

INDICATIONS
Late-Stage RP (mutation independent)

MODALITY
Optogenetic Platform

STAGE
Preclinical

Acquired by Novartis
RD Fund 1